



Robert Greene Sterne Jorge A. Goldstein David K.S. Cornwell Robert W. Esmond Tracy-Gene G. Durkin Michael B. Ray Robert E. Sokohl Fric K. Steffe Michael Q. Lee Steven R. Ludwig John M. Covert Robert C. Millonia Timothy J. Shea, Jr Michael V. Messinger Judith U. Kim Patrick E. Garrett

Jeffrey T. Helvey Eldora L. Ellison Thomas C. Fiala Donald R. Banowit Peter A. Jackman Jeffrey S. Weaver Brian J. Del Buono Mark Fox Evens Edward W. Yee Vincent L. Capuano Virgil Lee Beaston Theodore A. Wood Elizabeth J. Haanes Joseph S. Ostroff Frank R. Cottingham Daniel A. Klein Jason D. Eisenberg Michael D. Specht

Tracy L. Muller Jon E. Wright LuAnne M. DeSantis Ann E. Summerfield Helene C. Carlson Cynthia M. Bouchez Timothy A. Doyle Gaby L. Longsworth Lori A. Gordon Laura A. Vogel Bryan S. Wade Bashir M.S. Ali Shannon A. Carroll Anhar F Khal Michelle K. Holoubek Marsha A. Rose Young Tang Christopher J. Walsh

W. Blake Coblentz* James J. Pohl* John T. Haran Mark W. Rygiel Kevin W. McCabe Michael R. Malek*

Registered Patent Agents Karen R. Markowicz Matthew J. Dowd Katrina Yulian Pei Ouach Bryan L. Skelton Robert A. Schwartzman Victoria S. Rutherford Simon J. Elliott Julie A. Heider Mita Mukherjee

Scott M. Woodhouse Liliana Di Nola-Baron Peter A. Socarras Jeffrey K. Mills Danielle L. Letting Steven C. Oppenheimer

Of Counsel Edward J. Kessler Kenneth C. Bass III Marvin C Guthrie

*Admitted only in Maryland * Admitted only in Virginia Practice Limited to Federal Agencies

(202) 772-8846

November 6, 2006

INTERNET ADDRESS: PCALVO@SKGF.COM

WRITER'S DIRECT NUMBER:

Art Unit 1636

Attn: Mail Stop RCE

Commissioner for Patents PO Box 1450 Alexandria, VA 22313-1450

Re:

U.S. Utility Patent Application

Application No. 09/921,143; Filed: August 3, 2001 Vascular Endothelial Growth Factor 2 For:

Inventor: Timothy A. COLEMAN Our Ref: 1488.100000N/PAJ/PAC

Sir:

Transmitted herewith for appropriate action are the following documents:

- 1. Credit Card Payment Form (PTO-2038) in the amount of \$790.00 to cover the Request for Continued Examination (RCE) fee;
- 2. Request for Continued Examination (RCE) Transmittal Form;
- 3. Tenth Supplemental Information Disclosure Statement Under 37 C.F.R. § 1.97(b);
- 4. Two pages of Form PTO/SB/08A listing documents US10-US35 and FP13-FP20;
- 5. Copies of FP13-FP20 as listed on Form PTO/SB/08A; and
- 6. Return postcard.

It is respectfully requested that the attached postcard be stamped with the date of filing of these documents, and that it be returned to our courier.

In the event that extensions of time are necessary to prevent abandonment of this patent application, then such extensions of time are hereby petitioned.

Sterne, Kessler, Goldstein & Fox PLL.C.: 1100 New York Avenue, NW: Washington, DC 20005: 202.371.2600 f 202.371.2540: www.skgf.com

Commissioner for Patents November 6, 2006 Page 2

The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 19-0036.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.

Paul A. Calvo

Agent for Applicant Registration No. 57,913

PAJ/PAC/dbj Enclosures

600893_1.DOC

Sterne, Kessler, Goldstein & Fox PLLC. : 1100 New York Avenue, NW : Washington, DC 20005 : 202.371.2600 f 202.371.2540 : www.skgf.com



In re application of:

COLEMAN, Timothy A.

Appl. No.: 09/921,143

Filed: August 3, 2001

For: Vascular Endothelial Growth

Factor 2

Confirmation No.: 6449

Art Unit:

1636

Examiner:

QIAN, Celine X.

Atty. Docket: 1488.100000N/PAJ/PAC

Tenth Supplemental Information Disclosure Statement Under 37 C.F.R. § 1.97(b)

Mail Stop RCE

Commissioner for Patents PO Box 1450 Alexandria, VA 22313-1450

Sir:

Listed on accompanying IDS Form, PTO/SB/08A, are documents that may be considered material to the examination of this application, in compliance with the duty of disclosure requirements of 37 C.F.R. §§ 1.56, 1.97 and 1.98. The numbering on this Tenth Supplemental Information Disclosure Statement is a continuation of the numbering in Applicants' Ninth Supplemental Information Disclosure Statement filed on April 21, 2006 in connection with the above-captioned application.

Copies of documents FP13 to FP20 are submitted. However, in accordance with 37 C.F.R. § 1.98(a)(2), copies of U.S. patents and patent application publications, documents US10 to US35, cited on the attached IDS Form, PTO/SB/08A, are not submitted.

Where the publication date of a listed document does not provide a month of publication, the year of publication of the listed document is sufficiently earlier than the effective U.S. filing date and any foreign priority date so that the month of publication is not in issue. Applicants have listed publication dates on the attached IDS Form based on information presently available to the undersigned. However, the listed publication dates should not be construed as an admission that the information was actually published on the date indicated.

COLEMAN, Timothy A. Appl. No. 09/921,143

- 2 -

Applicants reserve the right to establish the patentability of the claimed invention over any of the information provided herewith, and/or to prove that this information may not be prior art, and/or to prove that this information may not be enabling for the teachings purportedly offered.

This statement should not be construed as a representation that a search has been made, or that information more material to the examination of the present patent application does not exist. The Examiner is specifically requested not to rely solely on the material submitted herewith.

This Information Disclosure Statement is being filed before the mailing of a first Office Action after the filing of a request for continued examination under 37 C.F.R. § 1.114. No statement or fee is required.

It is respectfully requested that the Examiner initial and return a copy of the enclosed IDS Forms, and indicate in the official file wrapper of this patent application that the documents have been considered.

The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 19-0036.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.

Paul A. Calvo

Agent for Applicants Registration No. 57,913

Date: 11/6/06 1100 New York Avenue, N.W. Washington, D.C. 20005-3934 (202) 371-2600

576314v1

Equivalent of Form PTO/SB/08A (07-05) Approved for use through 07/31/2006.
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Application Number

First Named Inventor

Attorney Docket Number

Complete if Known

09/921,143

August 3, 2001

Timothy A. COLEMAN

1488.100000N/PAJ/PAC

Substitute for form 1449/PTO

Sheet

NOV 0 6 2006

TENTH SUPPLEMENTAL INFORMATION DISCLOSURE STATE

2003/0187001 A1

US29

of

EMENT BY APPLICANT	Art Unit	1636
(Use as many sheets as necessary)	Examiner Name	QIAN, Celine X.

Filing Date

			U.S. PATENT DO	DCUMENTS		
	Cite No.1	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages	
muais	No.	Number-Kind Code ^{2 (If Known)}	WIWI-DD-1111	Applicant of Cited Document	or Relevant Figures Appear	
	US10	6,297,238	10/02/2001	Doyle et al.		
	US11	6,515,105	02/04/2003	Alitalo et al.		
	US12	6,660,744	12/09/2003	Hirst et al.		
	US13	6,713,474	03/30/2004	Hirst et al.		
	US14	6,764,820	07/20/2004	Ferrell et al.		
-	US15	6,824,777	11/30/2004	Alitalo et al.		
	US16	2002/0013261 A1	01/31/2002	Pawliuk et al.		
	US17	2002/0019350 A1	02/14/2002	Levine et al.		
	US18	2002/0034501 A1	03/21/2002	Pawliuk et al.		
	US19	2002/0086004 A1	07/04/2002	Adnot et al.		
	US20	2002/0111362 A1	08/15/2002	Rubinfeld, Joseph		
	US21	2002/0151489 A1	10/17/2002	Gravereaux et al.		
	US22	2002/0155421 A1	10/24/2002	Kearney et al.		
	US23	2002/0156081 A1	10/24/2002	Hirst et al.		
	US24	2003/0103943 A1	06/05/2003	Rosengart et al.		
	US25	2003/0125523 A1	07/03/2003	Alitalo et al.		
	US26	2003/0153752 A1	08/14/2003	Hirst et al.		
	US27	2003/0165464 A1	09/04/2003	Enholm et al.		
	US28	2003/0180286 A1	09/25/2003	Carmeliet et al.		

FOREIGN PATENT DOCUMENTS					
Examiner Cite Initials* No.1		1	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	
Country Code ³ Number ⁴ Kind Code ⁵ (if known)			T		
	FP13	WO 00/21560 A1	04/20/2000	Ludwig Institute for Cancer Research; Helsinki University Licensing Ltd. OY	
	FP14	WO 00/24412 A2	05/04/2000	Ludwig Institute for Cancer Research; Helsinki University Licensing Ltd. OY	
				Ludwig Institute for Cancer Research; Helsinki University Licensing Ltd. OY; University of Pittsburgh of the Commonwealth System of	
	FP15	WO 00/58511 A1	10/05/2000	Higher Education	╙
	FP16	WO 00/61186 A1	10/19/2000	Weichselbaum, Ralph R.	
	FP17	WO 00/62798 A2	10/26/2000	St. Elizabeth's Medical Center, Inc.	
	FP18	WO 01/52904 A2	07/26/2001	Gill, Parkash S.	

Calderwood et al.

10/02/2003

576305.1

Examiner	Date	
Signature	Considered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 'Applicant's unique citation designation number (optional). 'See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 'Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 'For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 'Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 'Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 house to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Equivalent of Form PTO/SB/08A (07-05)
Approved for use through 07/31/2006.
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

NOV 0 6 2006

TENTH SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 2 of 2

Complete if Known			
Application Number	09/921,143		
Filing Date	August 3, 2001		
First Named Inventor	Timothy A. COLEMAN		
Art Unit	1636		
Examiner Name	QIAN, Celine X.		
Attorney Docket Number	1488.100000N/PAJ/PAC		

U.S. PATENT DOCUMENTS						
Examiner Cite Initials No.1	Cite No.1	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages	
mitials		Number-Kind Code ^{2 (If Known)}			or Relevant Figures Appear	
	US30	2003/0211988 A1	11/13/2003	Epstein, Stephen E.		
	US31	2004/0002140 A1	01/01/2004	Gilbert et al.		
	US32	2004/0006083 A1	01/08/2004	Hirst et al.		
	US33	2004/0031067 A1	02/12/2004	Herlyn et al.		
	US34	2004/0248781 A1	12/09/2004	Kerbel, Robert	·	
	US35	2005/0118180 A1	06/02/2005	Rubinfeld, Joesph		
		11-11-11				
<u> </u>						
			 			
		-	<u> </u>			
			 			
		 				
		-				
			 			

FOREIGN PATENT DOCUMENTS					
Examiner Initials*	Cite No.1	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	
		Country Code ³ Number ⁴ Kind Code ⁵ (if known)			Τ ⁴
				Ludwig Institute for Cancer Research; Flanders	Г
	FP19	WO 03/000009 A2	01/03/2003	Interuniversity Institute for Biotechnology	
	FP20	WO 03/015755 A1	02/27/2003	Ramot At Tel Aviv University Ltd.	
					Π
					T
	,		-		

576305.1

Examiner	Date	
Signature	Considered	

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant's unique citation designation number (optional). *See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. *Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). *For Japanese patent documents, the indication of the year of the region of the Emperor must precede the serial number of the patent document. *Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. *Applicant is to place a check mark here if English language Translation is attached.